New drug study aims to transform care for rare blood disorder
NCT ID NCT06931691
Summary
This study is observing how a drug called iptacopan affects adults in China with a rare blood disease called paroxysmal nocturnal hemoglobinuria (PNH). It will follow 80 patients who are starting this new treatment to see if it improves their blood counts, reduces symptoms, and changes how much medical care they need. The goal is to understand the real-world benefits and management of this condition with the new medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
RECRUITINGShijiazhuang, Hebei, 050000, China
-
Novartis Investigative Site
RECRUITINGZhengzhou, Henan, 450008, China
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430030, China
-
Novartis Investigative Site
RECRUITINGNanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
RECRUITINGChangchun, Jilin, 130021, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300020, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300052, China
-
Novartis Investigative Site
RECRUITINGWuhan, 430022, China
Conditions
Explore the condition pages connected to this study.